Ed Silverman
Cooperation among drugmakers is needed to make these group-effort trials work
Interview by Peter Wehrwein
Richard L. Schilsky, MD
Supportive care has transformed the patient experience. More drugs than ever are gaining FDA approval. But ASCO’s chief medical officer says the high cost of new treatments causes harm and needs to be addressed.
Interview by Robert Calandra

Jennifer Malin, MD

In the era of the $10,000-a-month drug, clinical pathways are the best hope for reining in costs and getting patients the care they need, says the vice president for clinical strategies at Anthem.
Interview by Peter Wehrwein

Michael Kolodziej, MD

Aetna’s national medical director for oncology solutions argues that “variation almost never yields a superior result.” Stick to optimized practices.
Original Research
Timothy Kubal, MD, MBA
John W. Peabody, MD, PhD, FACP
Eliot Friedman, MD
An Early Report on the Moffitt Oncology Network Initiative
Legislation & Regulation
Richard Mark Kirkner

James C. Robinson

Designed to pay for breakthroughs, the new technology add-on (NTAP) ‘bump’ is also too unpredictable, say drug and device groups.

Tomorrow's Medicine
Thomas Morrow, MD

Childhood cancer hasn’t been a big money maker. A not-for-profit helped fund the research that led to the approval of a new drug for neuroblastoma.

News & Commentary

"Arterial kateter (Seldinger)" by Privatarchiv Foto von MrArifnajafov

News & Commentary
Frank Diamond